Duration of Current Statin Use and Amyotrophic Lateral Sclerosis Risk: A Norwegian Population-Based Cohort Study

Area of Science:

• Neurology
• Cardiovascular Science
• Epidemiology

Background:

• Hypercholesterolemia may influence long-term amyotrophic lateral sclerosis (ALS) risk.
• Elevated cholesterol can be a secondary effect in the prediagnostic phase of ALS.

Purpose of the Study:

• Investigate the association between short-term and long-term statin use and subsequent ALS risk.
• Clarify the role of statins in ALS etiology.

Main Methods:

• A Norwegian cohort study linked health survey data with nationwide administrative records.
• Statin use duration was analyzed as time-varying exposure (0-1 year, 1-5 years, 5-17 years).
• Cox regression models adjusted for multiple cardiovascular risk factors and demographics were employed.

Main Results:

• Short-term statin use (0-1 year) was associated with a significantly increased ALS risk (HR 3.56).
• Long-term statin use (1-5 years and 5-17 years) showed a reduced ALS risk (HRs 0.85 and 0.67).
• These associations were more pronounced in men, with short-term use increasing risk (HR 4.03) and long-term use decreasing it (HR 0.47).

Conclusions:

• The increased ALS risk with short-term statin use suggests reverse causality, with statins initiated due to prediagnostic symptoms.
• Long-term statin use demonstrated a protective effect against ALS, especially in men.
• Further research is needed to understand the complex relationship between statins, cholesterol, and ALS.